Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PIZV (TAK-426) in Healthy Adults
NCT05469802Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Jan 2024
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of purified inactivated Zika virus vaccine in Zika virus infection, sponsored by Takeda. Planned start Jan 2024; status: withdrawn.
02
Drugs
purified inactivated Zika virus vaccine
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT05469802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469802.